2. Immunology/Inflammation
  3. Macrophage migration inhibitory factor (MIF)
  4. 4-IPP

4-IPP  (Synonyms: 4-Iodo-6-phenylpyrimidine)

Cat. No.: HY-110063 Purity: 99.40%
COA
SDS
Handling Instructions Technical Support

4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).

For research use only. We do not sell to patients.

CAS No. : 41270-96-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

4-IPP Related Antibodies

Top Publications Citing Use of Products

    4-IPP purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Dec 15;135(24):e193082.  [Abstract]

    Illustration of experimental design (top) and cell counts (bottom) of AML cells cocultured with CD81+ Erys pretreated with either 10 μM 4-IPP or DMSO (n = 5).

    4-IPP purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Aug 1.  [Abstract]

    BMMCs were treated with Dara  ± inhibitors (Belimumab [BAFF], 4-IPP [MIF], and MYCi975 [MYC]) for 24 h, then co-cultured with NK-cells at an effector:target (E:T) ratio = 1:1 for 12 h. The amount of released LDH was determined using a cytotoxicity assay kit to calculate the % of lysed cells.

    4-IPP purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jan 31;44(1):33.  [Abstract]

    4-IPP (5 mg/kg, IP, every 2 days for 15 days). In vivo, inhibition of MIF and p-STAT3 can reduce tumor size.

    4-IPP purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jan 31;44(1):33.  [Abstract]

    4-IPP (5 mg/kg, IP, every 2 days for 15 days). Flow cytometry results demonstrate that inhibition of MIF and p-STAT3 decrease the number of CD74+ PDGFRB+ cells.

    4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600.  [Abstract]

    4-IPP (80 mg/kg, intraperitoneal therapy). MIF inhibitors significantly inhibited the growth of gastric cancer.

    4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600.  [Abstract]

    4-IPP (80 mg/kg, intraperitoneal therapy). Immunofluorescence revealed the infiltration level of T cells in the MIF-inhibited group and the control group.

    4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600.  [Abstract]

    4-IPP (80 mg/kg, intraperitoneal therapy). Flow cytometry was used to analyze the proportion and cytotoxicity of CD4+ T cells in the MIF inhibitor and control groups.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1].

    IC50 & Target

    MIF[1]
    In Vitro

    4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1].
    4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1].
    4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1].
    4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1].
    4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    4-IPP Related Antibodies

    Cell Cytotoxicity Assay[1]

    Cell Line: BMMs
    Concentration: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM
    Incubation Time: 24 hours, 72 hours
    Result: Inhibited osteoclastogenesis in a dose-dependent manner.

    Western Blot Analysis[1]

    Cell Line: BMMs
    Concentration: 5 μM,10 μM, 20 μM
    Incubation Time: 1 day, 3 days, 5 days
    Result: Inhibited RANKL-induced osteoclast differentiation and bone resorption.
    In Vivo

    4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 8-weeks-old C57BL/6J male mice[1]
    Dosage: 1 mg/kg, 5 mg/kg
    Administration: Intraperitoneal injection; every 2 days; for 8 weeks
    Result: Alleviated OVX-induced osteoporosis.
    Molecular Weight

    282.08

    Formula

    C10H7IN2
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    IC1=CC(C2=CC=CC=C2)=NC=N1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (354.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.5451 mL 17.7255 mL 35.4509 mL
    5 mM 0.7090 mL 3.5451 mL 7.0902 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.40%

    SDS (476 KB)

    COA (248 KB) HNMR (241 KB) RP-HPLC (233 KB) LCMS (95 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5451 mL 17.7255 mL 35.4509 mL 88.6273 mL
    5 mM 0.7090 mL 3.5451 mL 7.0902 mL 17.7255 mL
    10 mM 0.3545 mL 1.7725 mL 3.5451 mL 8.8627 mL
    15 mM 0.2363 mL 1.1817 mL 2.3634 mL 5.9085 mL
    20 mM 0.1773 mL 0.8863 mL 1.7725 mL 4.4314 mL
    25 mM 0.1418 mL 0.7090 mL 1.4180 mL 3.5451 mL
    30 mM 0.1182 mL 0.5908 mL 1.1817 mL 2.9542 mL
    40 mM 0.0886 mL 0.4431 mL 0.8863 mL 2.2157 mL
    50 mM 0.0709 mL 0.3545 mL 0.7090 mL 1.7725 mL
    60 mM 0.0591 mL 0.2954 mL 0.5908 mL 1.4771 mL
    80 mM 0.0443 mL 0.2216 mL 0.4431 mL 1.1078 mL
    100 mM 0.0355 mL 0.1773 mL 0.3545 mL 0.8863 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    4-IPP Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    4-IPP41270-96-64-Iodo-6-phenylpyrimidineMacrophage migration inhibitory factor (MIF)MIFRANKLosteoclastogenesisosteoblastInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    4-IPP
    Cat. No.:
    HY-110063
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (476 KB) Français - FR (476 KB) Deutsch - DE (476 KB) Norwegian - NO (476 KB) Español - ES (476 KB) Swedish - SV (476 KB) Italian - IT (476 KB) Korean - KR (476 KB) Portuguese - PT (476 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.